CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞在多发性骨髓瘤不断演变的治疗格局中的作用：文献综述
英文原题：Role of Chimeric Antigen Receptor T-Cells in the Evolving Therapeutic Landscape of Multiple Myeloma: A Literature Review.
查看英文原题
Role of Chimeric Antigen Receptor T-Cells in the Evolving Therapeutic Landscape of Multiple Myeloma: A Literature Review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤（MM）是一种浆细胞恶性肿瘤，尽管治疗有所进展，复发/难治性疾病仍是重大挑战。CAR-T（CAR-T）细胞疗法通过基因工程改造患者T细胞，使其表达可识别肿瘤相关抗原的受体，已在MM治疗中显示出显著疗效。本综述概述CAR-T 细胞的作用机制、临床有效性及安全性，并讨论其在MM中的应用前景和当前挑战。
展开英文摘要原文
Multiple myeloma (MM) is a quotidian malignant disorder of plasma cells. It is hallmarked by the uncontrolled growth of bone marrow plasma cells, leading to multiorgan dysfunction. Despite ongoing advancements in remedies, including chemotherapy, radiotherapy, immunomodulatory drugs, stem cell transplantations, and countless other lines of treatment, the management of MM remains a challenge.
Recent studies indicate promising outcomes with chimeric antigen receptor T-cell (CAR-T) therapy, especially in patients who have previously undergone other treatments. This literature review aims to explore various facets of MM and the progress made with CAR-T therapy, emphasizing the mechanism, effectiveness, and safety profile.
论文信息
- 作者
- Radhi M、Yusuf DA、AlSaffar GM、Toorani ZA
- 第一作者单位
- General Medicine, Royal College of Surgeons in Ireland (RCSI) - Medical University of Bahrain, Busaiteen, BHR.Ireland
- 通讯作者单位
- Pathology, Salmaniya Medical Complex, Manama, BHR.
- 文献类型
- 综述
- 期刊
- Cureus2025 Mar
- 原文标识
- PubMed 40190972 · DOI 10.7759/cureus.80068
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →